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Introduction: The biomarker soluble urokinase plasminogen activator receptor (suPAR)
has been associated with increased mortality in chronic obstructive pulmonary disease
(COPD), while elevated blood eosinophils have been associated with better survival. We
hypothesized that suPAR and blood eosinophil count are independent risk factors for read-
mission and mortality after an acute admission in patients with COPD.
Methods: This retrospective cohort study comprised 4022 patients with prevalent COPD acutely
admitted to Hvidovre Hospital, Denmark. Irrespective of cause of admission, suPAR and blood
eosinophils were measured, and patients were followed up to 365 days. Associations with 365-day
respiratory readmission, all-cause readmission and all-cause mortality were investigated by Cox
regression analyses adjusted for age, sex, Charlson score and C-reactive protein.
Results: suPAR was significantly elevated in patients who later experienced readmission or died.
At 365 days, hazard ratios (HRs) for all-cause readmission and mortality reached 1.61 (95% CI
1.40–1.85; p<0.0001) and 3.40 (95% CI 2.64–4.39; p<0.0001), respectively, for COPD patients in
the fourth suPAR quartile compared to patients in the first suPAR quartile. High blood eosinophils
(>300 cells/μL) were associated with lower risk of mortality (HR 0.49, 95% CI 0.39–0.62;
p<0.0001) compared with patients with <150 cells/μL. When stratifying patients by suPAR
quartiles and blood eosinophil counts, the highest relative mortality rate was found in patients
belonging to both the fourth suPAR quartile and the low blood eosinophil (<150 cells/μL) group.
Conclusion: In this cohort of COPD patients acutely admitted to a hospital, elevated suPAR
concentrations were associated with both higher risk of all-cause readmission and mortality,
whereas higher blood eosinophil count was associated with lower risk of mortality.
Keywords: acute admission, biomarker, hospitalization, prognosis, retrospective cohort,
inflammation
Introduction
Chronic obstructive pulmonary disease (COPD) is one of the world’s most common
chronic diseases, posing a considerable economic and social burden worldwide.1 COPD
is characterized by a decline in lung function and overall health status as well as acute
exacerbations of COPD (AECOPD). As COPD progresses, patients often experience
repeated hospitalizations due to exacerbations and comorbidities. Besides major impacts
on quality of life and healthcare-associated costs,2 all-cause readmissions have been
shown to be an independent risk factor of COPDmortality.3,4 This highlights the need for
novel risk prediction tools to help identifying hospitalized COPD patients at high risk of
future readmission and mortality.
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Several prognostic markers for hospitalization and/or
COPD-related mortality have been suggested, such as pre-
sence of emphysema and severity of airflow limitation,5,6 but
reliable biomarkers for COPD readmission and mortality risk
are yet to be found. suPAR is the soluble form of the uroki-
nase plasminogen activator receptor (uPAR), a membrane
receptor consisting of three domains (DI, DII and DIII).
uPAR is expressed on a range of cells such as lymphocytes,
monocytes, endothelial and smooth muscle cells, where
uPAR and its soluble form are a central part of the plasmin/
plasminogen pathway and are involved in chemotaxis,
immune system activation and tissue remodeling. As such,
suPAR is considered a broadly applicable inflammatory mar-
ker in both acute and chronic disease with associations ran-
ging from diabetes and arrhythmias to acute all-cause
mortality.7–9
In COPD, suPAR is associated with small airway fibrosis
and emphysema through complex molecular and genetic
pathways,10 and neutrophils are thought to be a central source
of circulating suPAR.11,12 Furthermore, studies have shown
that suPAR is elevated in patients with stable COPD com-
pared to healthy controls,13 as well as being a biomarker of
poor prognosis and increased 90-day mortality in COPD
patients in an emergency department (ED) setting.14
Another area of interest in COPD biomarkers are eosi-
nophils, neutrophils and their resulting inflammatory pro-
files. Both types of inflammation have been associated to
adverse outcomes in (AE)COPD.15–17 In eosinophilic
inflammation, higher and, in particular, fluctuating blood
eosinophil counts have been suggested as risk markers for
unstable disease and exacerbations.18 The GOLD 2019
guidelines have introduced blood eosinophil count as
a possible biomarker to identify at-risk patients and candi-
dates for inhaled corticosteroid treatment.1 Despite the
recent surge in inflammatory profile research and the
roles of eosinophils and other inflammation markers in
COPD, our knowledge of their roles in clinical outcomes
is still limited. Furthermore, little is known about the
relationship between suPAR and blood eosinophils, but
with suPAR being thought to stem from activated
neutrophils,11 we hypothesize that they may reflect sepa-
rate inflammatory mechanisms and as such provide dis-
tinct clinical information about adverse outcomes in
COPD when measured in combination.
We have previously shown that suPAR is associated
with 30- and 90-day mortality in acutely admitted patients
with COPD.14 Here, we hypothesize that plasma suPAR
and blood eosinophil count are independently associated
with both long-term (365-days) readmission and mortality
in patients acutely admitted with COPD as either primary
or secondary diagnosis.
Materials and Methods
Ethics
The study was approved by the Danish Health and
Medicines Authority (ref. 3-3013-1061/2) and the Danish
Data Protection Agency (ref. HVH-2014-018, 02767).
Study Subjects and Study Design
This study is based on a retrospective, registry-based cohort
study of 29,088 medical patients who were acutely admitted
to the ED, Copenhagen University Hospital Amager and
Hvidovre, Hvidovre, Denmark, from November 18, 2013,
to March 17, 2017. The follow-up period ended June 17,
2017, ensuring follow-up of minimum 90 days for all
patients. The ED receives unselected, adult internal medicine
patients of all specialties except patients suspected of gastro-
enterological diseases, as previously described.14 In this
study, we included all patients who 1) were admitted to the
ED during the study period, 2) had a diagnosis of COPD
(ICD-10: J440, J441, J449) registered before (within the past
2 years) or during the admission, and 3) had suPAR concen-
trations measured as part of the standard admission blood
tests. suPAR and mortality data on a subgroup (n=2838) of
this COPD cohort has previously been published.14
The index admission was defined as the first admission
where a patient had suPAR measured. Data on suPAR and
blood eosinophil count were obtained via the electronic
hospital database LABKA. All data on diagnoses and admis-
sions were obtained from the Danish National Patient
Registry. Vital status was obtained from the Danish Civil
Registration System.19 Follow-up was at 30, 90 or 365 days.
The Charlson comorbidity index (Charlson score) was used
to create a compound score of disease burden due to comor-
bidities, based on concurrent ICD-10 diagnoses on a per-
patient basis. The score was used to correct for co/multi-
morbidity in our multivariate analyses and was calculated
using a SAS macro20 with updated weights as defined by
Quan et al.21 All primary and secondary diagnoses registered
in the National Patient Registry for the past 2 years before the
index admission were used to calculate the score. The 17
original Charlson groups were collapsed into 9 major comor-
bidity groups (the Charlson group “Chronic Pulmonary
Disease” was omitted): Cardiovascular disease (comprised
of the Charlson groups “Myocardial Infarction”, “Congestive
Håkansson et al Dovepress
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Heart Failure”, “Peripheral Vascular Disease”, and
“Cerebrovascular Disease”), “Dementia”, “Peptic Ulcer
Disease”, Liver Disease (“Mild Liver Disease” and
“Moderate or Severe Liver Disease”), Diabetes ("Diabetes
without Chronic Complications", "Diabetes with Chronic
Complications"), “Renal Disease”, Cancer (“Cancer”,
“Metastatic Carcinoma”), and Other (“Connective Tissue
Disease-Rheumatic Disease”, “Hemiplegia and Paraplegia”,
“AIDS/HIV”). In addition, we registered whether patients
had a history of acute exacerbations (ICD-10: J441) in the
past 2 years before the index admission, and whether the
following specific comorbidities were present in the past 2
years before or during the index admission: Hypertension
(ICD-10: I10-I15), Myocardial Infarction (ICD-10: I21, I22,
I252), Stroke (ICD-10: I61, I63, I649), Type 2 Diabetes
(ICD-10: E11), and Lung Cancer (ICD-10: C34). We identi-
fied causes of admissions as A-diagnoses (primary diag-
noses) registered for the index admission or readmissions,
based on ICD-10 chapters, as shown in Table 2. In addition,
we identified the following specific respiratory diagnoses as
causes of admissions/readmissions: acute upper respiratory
infections (ICD-10: J00–06), influenza or pneumonia (ICD-
10: J09–18), other acute lower respiratory infections (ICD-
10: J20–22), chronic lower respiratory diseases (ICD-10:
J40–47), acute respiratory distress syndrome or pulmonary
edema (ICD-10: J80–81), other interstitial pulmonary dis-
eases (ICD-10: J84), pleural effusion (ICD-10: J90–91),
pneumothorax (ICD-10: J93), and respiratory failure (ICD-
10: J96). It should be noted that a patient can have more than
one cause of admission/readmission, e.g., if a patient was
transferred between wards during the admission.
Measurements
Admission blood tests were analyzed at the Department of
Clinical Biochemistry, Hvidovre Hospital. Plasma suPAR
concentrations were measured using the suPARnostic
AUTO Flex ELISA kit (ViroGates A/S, Birkerød,
Denmark).7 The suPARnostic® ELISA measures the full
length (DI-DIII) and the cleaved (DIIDIII) suPAR molecules.
Blood eosinophil counts were measured using Sysmex
XE5000 (Sysmex Corporation, Kobe, Japan; until
February 2015) and Sysmex XN9000 (from February 2015)
analyzers. C-reactive Protein (CRP) was measured using
a COBAS 6000 analyzer (Roche Diagnostics, Mannheim,
Germany).
Statistical Analyses
Primary outcomes were acute (unplanned) readmission and
all-cause mortality within 365 days from the index admis-
sion. Secondary outcomes were identical outcomes within
30 or 90 days. Data on secondary outcomes are presented in
the Supplementary Material. For readmissions, we examined
all-cause readmissions and respiratory readmissions (i.e.,
the first readmission for any of the following respiratory
ICD-10 diagnoses, regardless of whether another
non-respiratory readmission had transpired before: J00–06,
J09–18, J20–22, J40–47, J80–81, J84, J90–91, J93, J96).
Continuous variables are presented as median and
interquartile range (IQR), and categorical variables are
presented as number (n) and percentages (%).
Population-specific suPAR quartiles were generated.
To create categorical blood eosinophils groups, cut-offs
were defined as low eosinophils (<150 cells/μL), inter-
mediate eosinophils (150–300 cells/μL) and high eosino-
phils (>300 cells/μL).1,22,23 Results from blood eosinophil
analyses were available for 97.5% of the patients.
Unadjusted and multivariable adjusted Cox regression
analyses were used to estimate the association of suPAR,
continuous (log2-transformed) and categorical (quartiles),
with risk of readmission and mortality in separate models.
Similar models were fitted for eosinophils (log2-transformed
or low/intermediate/high blood eosinophil count). Results
are presented as hazard ratios (HRs) with 95% confidence
intervals (CIs). The adjusted models include the following
variables: age, sex, Charlson score, CRP, suPAR and eosino-
phils. In the Cox regression analyses of readmission, death
before readmission was considered a competing endpoint.
The HR for readmission is therefore calculated for the cause-
specific hazard of readmission, with censoring at the time of
death. The proportional hazards assumption was evaluated
by the Schoenfeld residuals; if fits violated the assumption,
modifications were made to the model by stratifying the
hazard by the adjusted variables. The discriminative ability
of suPAR and blood eosinophil count to predict 365-day
readmission and mortality was analyzed using area under
the curve (AUC) for receiver operating characteristics
(ROC) curves. We calculated sensitivity, specificity, positive
predictive value (PPV), and negative predictive value (NPV)
at cut-off values determined using Youden’s index24 or the
cut-off for the highest suPAR quartile or 150 cells/μL for
blood eosinophil count.
Dovepress Håkansson et al
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Cumulative incidence plots for survival and readmis-
sion stratified by suPAR quartiles are presented to illus-
trate the outcome distribution of COPD patients over time.
SAS Enterprise Guide 7.11 (SAS Institute Inc, Cary, NC)
and R 3.60 (R Foundation for Statistical Computing, Vienna,
Austria) were used for statistical analysis. R 3.60 was used to
create the figures. A P-value <0.05 was considered statisti-
cally significant.
Results
A total of 29,088 patients were admitted to the ED and had
suPAR analyzed during the study period. Of these patients,
4022 (55.5%women, median age 73.1 years) had a prevalent
COPD diagnosis and were included in the present study. The
median length of stay was 2.1 days (Table 1).
The most common comorbidities were cardiovascular
diseases (25.1%) and diabetes (13.4%). Of all patients,
19.5% had a history of at least one acute exacerbation within
the past two years (Table 1). For half of the patients, the
primary cause of index admission was respiratory disease
(n=1982, 49.3%), with the most common diagnosis being
chronic lower respiratory disease (n=941) (Table 2).
At the index admission, COPD patients had a median
suPAR of 3.9 ng/mL and a median blood eosinophil count
of 100 cells/μL (Table 1). The mean follow-up time was
297.8 days (SD 125.6). During this period, 2326 patients
(57.8%) were readmitted for any cause (of which 938
(40.3%) were due to respiratory diagnoses), and 1268
patients (31.5%) had a respiratory readmission (Table 2).
Of the patients, 26.1% died within 365 days (Table 3).
suPAR in COPD
COPD patients who were readmitted due to respiratory diag-
noses had significantly higher median suPAR at the time of
index admission compared to event-free patients (4.0
(2.9–5.5) vs 3.3 (2.6–4.4) ng/mL, p<0.0001). Similarly for
all-cause readmissions, patients who were later readmitted
had significantly higher median suPAR at the time of index
admission compared to event-free patients (4.1 (IQR 3.0–5.7)
vs 3.3 (IQR 2.6–4.4) ng/mL, p<0.0001) (Table 3). When
stratified into suPAR quartiles, higher readmission rates
were observed with increasing suPAR quartiles (Figure 1).
In univariate Cox regression analyses, elevated suPAR
was associated with increased risk of both respiratory and
all-cause readmission in COPD patients (Table 4). When
adjusting for age, sex, Charlson score, CRP and blood
eosinophils, only all-cause readmission remained
associated with suPAR (365 days HR for fourth vs first
suPAR quartile: 1.61, 95% CI 1.40–1.85) (Table 4).
COPD patients who died during follow-up had signifi-
cantly higher median suPAR at the time of index admission
compared to event-free patients (5.3 (IQR 3.8–7.1) vs 3.3
ng/mL (IQR 2.6–4.4) ng/mL, p<0.0001) (Table 3). All-cause
mortality increasedwith increasing suPARquartiles (Figure 1),
reaching an HR of 3.40 (95% CI 2.64–4.39) in the fourth
quartile vs the first quartile at 365 days after adjusting for
age, sex, Charlson score, CRP and blood eosinophils (Table 4).
In ROC curve analyses, the AUCs for suPAR were 0.53
(95% CI 0.51–0.55) for predicting all-cause readmission
(Supplementary Figure 1) and 0.71 (95% CI 0.69–0.72) for
predicting mortality (Supplementary Figure 2).
The clinical performance of suPAR was evaluated
using sensitivity/specificity analyses for cut-offs deter-
mined by 1) Youden’s index (YI) and 2) the fourth
Table 1 Baseline Characteristics of Patients Acutely Hospitalized
with Prevalent COPD
N (%) or
Median (IQR)
Total N 4022
Men 1803 (44.8%)
Women 2219 (55.2%)
Age (years) 73.1 (63.7–81.1)
Comorbidities:
Hypertensiona 1009 (25.1%)
Cardiovascular disease 1010 (25.1%)
Myocardial infarction 165 (4.1%)
Stroke 224 (5.6%)
Dementia 162 (4.0%)
Peptic ulcer disease 101 (2.5%)
Liver disease (mild and moderate/severe) 113 (2.8%)
Diabetes (with and without complications) 538 (13.4%)
Type 2 diabetes 520 (12.9%)
Renal disease 148 (3.7%)
Cancer 448 (11.1%)
Lung cancer 149 (3.7%)
Other comorbiditiesb 97 (2.4%)
Charlson score 1 (1–2)
History of acute exacerbations in past 2 years 785 (19.5%)
Length of hospital stay (days) 2.1 (0.6–6.7)
C-reactive protein (mg/L), n=3848 16.0 (4.0–65.0)
Blood eosinophil count (cells/μL), n=3849 100 (20–220)
suPAR (ng/mL) 3.9 (2.9–5.6)
Notes: aThe category "Hypertension" was defined as ICD-10 diagnoses I10-I15 and
was not part of the Charlson score. bThe category “Other comorbidities” includes
the Charlson groups connective tissue disease – rheumatic isease (n=72), hemi-
plegia and paraplegia (n=17), and AIDS/HIV (n=9).
Abbreviations: COPD, chronic obstructive pulmonary disease; IQR, interquartile
range; suPAR, soluble urokinase plasminogen activator receptor.
Håkansson et al Dovepress
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suPAR quartile cut-off. For predicting 365-day all-cause
readmission, a sensitivity of 54.3% and a specificity of
54.5% (PPV 62.2%, NPV 46.4%) were achieved using the
YI optimal cut-off of 3.9 ng/mL. Using the fourth quartile
cut-off (5.6 ng/mL) yielded a sensitivity of 26.7% and
specificity 76.2% (PPV 60.8%, NPV 43.0%).
For 365-day mortality, a sensitivity of 63.6% and
a specificity of 68.8% (PPV 41.9%, NPV 84.2%) were
Table 2 Causes of Index Admission and 365-Day Readmission in 4022 Patients with Prevalent COPD
Index Admissions N (%) First Readmission N (%) Total Respiratory
Readmissions N (%)
Total events 4022 (100) 2326 1268
Certain infections and parasitic diseases 191 (4.7) 132 (5.7)
Endocrine, nutritional and metabolic diseases 139 (3.5) 110 (4.7)
Circulatory diseases 441 (11.0) 252 (10.8)
Respiratory diseases 1982 (49.3) 938 (40.3)
Acute upper respiratory infections 17 (0.9)a 2 (0.2)a 5 (0.4)
Influenza or pneumonia 501 (25.3)a 252 (26.9)a 370 (29.2)
Other acute lower respiratory infections 21 (1.1)a 4 (0.4)a 7 (0.6)
Chronic lower respiratory diseases 941 (47.5)a 432 (46.1)a 554 (43.7)
Acute respiratory distress syndrome or pulmonary edema 6 (0.3)a 4 (0.4)a 4 (0.3)
Other interstitial pulmonary diseases 4 (0.2)a 3 (0.3)a 5 (0.4)
Pleural effusion 17 (0.9)a 7 (0.7)a 11 (0.9)
Pneumothorax 16 (0.8)a 9 (1.0)a 10 (0.8)
Respiratory failure 542 (27.3)a 300 (32.0)a 406 (32.0)
Diseases of the digestive system 108 (2.7) 121 (5.2)
Musculoskeletal and connective tissue disease 104 (2.6) 56 (2.4)
Diseases of the genitourinary system 119 (3.0) 94 (4.0)
Symptoms, signs, and abnormal findings 372 (9.2) 283 (12.2)
Factors influencing health status and contact with health services 416 (10.3) 208 (8.9)
Other causes of admissionb 338 (8.4) 316 (13.6)
Notes: aPercent of Respiratory disease (re)admissions. bCauses of admission are based on ICD-10 chapters. The category “Other causes of admission” includes the ICD-10
chapters: II “Neoplasms” and III “Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism” (n=89 for index admissions; n=79
for readmissions); V “Mental and behavioral disorders” (n=90 for index admissions; n=54 for readmissions); VI “Diseases of the nervous system” (n=35 for index admissions;
n=37 for readmissions); VII “Diseases of the eye and adnexa” and VIII “Diseases of the ear and mastoid process” (n=8 for index admissions; n=3 for readmissions); XII
“Diseases of the skin and subcutaneous tissue” (n=20 for index admissions; n=19 for readmissions); XV “Pregnancy, childbirth and the puerperium” (n=1 for index
admissions; n=3 for readmissions); and XIX “Injury, poisoning and certain other consequences of external causes” (n=98 for index admissions; n=127 for readmissions). It
should be noted that a patient can have more than one cause of admission/readmission, e.g., if a patient was transferred between wards during the admission.
Abbreviation: COPD – Chronic obstructive pulmonary disease.
Table 3 Rates of Readmission and Mortality Within 365 Days in 4022 Patients with COPD Following Hospitalization Stratified by
suPAR Quartiles or Blood Eosinophil Counts
No Event Respiratory Readmission All-Cause Readmission All-Cause Mortality
1275 (31.7%) 1268 (31.5%) 2326 (57.8%) 1051 (26.1%)
suPAR (ng/mL) 3.3 (2.6–4.4) 4.0 (2.9–5.5)* 4.1 (3.0–5.7)* 5.3 (3.8–7.1)*
First quartile (<2.9), n=980 437 (44.5%) 309 (31.5%) 511 (52.1%) 109 (11.1%)
Second quartile (2.9–3.8), n=1003 388 (38.7%) 286 (28.5%) 551 (54.9%) 175 (17.4%)
Third quartile (3.9–5.5), n=1014 268 (26.4%) 365 (36.0%) 643 (63.4%) 287 (28.3%)
Fourth quartile (≥5.6), n=1025 182 (17.8%) 308 (30.0%)* 621 (60.6%)* 480 (46.8%)*
Eosinophils (cells/μL) 120 (30–250) 100 (20–240)* 100 (30–230)* 50 (10–150)*
Low (<150), n=2366 678 (28.7%) 735 (31.1%) 1367 (57.8%) 746 (31.5%)
Intermediate (150–300), n=886 312 (35.2%) 266 (30.0%) 520 (58.7%) 169 (19.1%)
High (>300), n=597 222 (37.2%) 218 (36.5%)* 354 (59.3%)* 86 (14.4%)*
Notes: Values presented as percentages or median (IQR). Chi2-tests by increasing suPAR quartiles or blood eosinophil count groups, compared to patients without an event
during the follow-up period. *p<0.05 in comparison to “No event”
Abbreviations: COPD, chronic obstructive pulmonary disease; IQR, interquartile range; suPAR, soluble urokinase plasminogen activator receptor.
Dovepress Håkansson et al
International Journal of Chronic Obstructive Pulmonary Disease 2020:15 submit your manuscript | www.dovepress.com
DovePress
737
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
23
0.
20
0 
on
 0
7-
Ju
l-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
achieved using the YI calculated optimal cut-off of 4.5
ng/mL. Corresponding results using the fourth quartile
cutoff (5.6 ng/mL) were sensitivity 45.7% and specifi-
city 81.7% (PPV 46.8%, NPV 80.9%).
Blood Eosinophil Count in COPD
For patients with COPD, median blood eosinophil
count was significantly lower for patients who were
readmitted compared to patients without events
(Table 3), and a trend towards a lower risk of all-
cause readmission was seen in patients with high
blood eosinophil counts (>300 cells/μL) in the adjusted
Cox regression analysis (HR 0.90 (95% CI 0.80–1.02);
p=0.09) (Table 5).
COPD patients who died during follow-up had signifi-
cantly lower median blood eosinophil count at the time of
index admission compared to event-free patients (Table 3).
Of all deaths within 365 days, 71.0% (n=746) were observed
in patients with blood eosinophil counts <150 cells/µL
(Table 3). In patients with high blood eosinophil counts
(>300 cells/μL), the HR reached 0.49 (95% CI 0.39–0.62)
for 365-day mortality in the adjusted model (Table 5).
In ROC curve analyses, the AUC for blood eosinophil
count was 0.56 (95% CI 0.54–0.58) for predicting all-cause
readmission (Supplementary Figure 1) and 0.63 (95% CI
0.61–0.65) for predicting mortality (Supplementary
Figure 2).
For predicting 365-day all-cause readmission, a cut-off for
blood eosinophil count determined by YI of 5 cells/µLyielded
a sensitivity of 88.5% and a specificity of 16.7% (PPV 59.8%,
NPV 51.0%). Using the cut-off of 150 cells/µL yielded
a sensitivity of 39.0% and specificity of 62.0% (PPV 59.0%,
NPV 42.1%) for predicting 365-day readmission.
For predicting 365-day mortality, a cut-off for blood
eosinophil count determined by YI of 85 cells/µL yielded
a sensitivity of 62.5% and a specificity of 58.5% (PPV
34.6%, NPV 81.6%). Using the cut-off of 150 cells/µL
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Figure 1 Cumulative incidence plot of mortality (top) and readmission (bottom)
within 365 days, stratified by quartiles of suPAR, for 4022 patients acutely admitted
with chronic obstructive pulmonary disease.
Table 4 HRs for Readmission and Mortality Within 365 Days Following Hospitalization in Patients with COPD (n=4022), for
Continuous suPAR (Log2-Transformed) or Stratified by suPAR Quartiles
Respiratory Readmission All-Cause Readmission All-Cause Mortality
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Unadjusted
Continuous suPAR 1.18 (1.10–1.28) <0.0001 1.36 (1.29–1.44) <0.0001 2.20 (2.04–2.37) <0.0001
First suPAR quartileb 1 1 1
Second suPAR quartile 0.93 (0.80–1.10) 0.41 1.13 (1.00–1.27) 0.054 1.64 (1.29–2.08) <0.0001
Third suPAR quartile 1.30 (1.11–1.51) 0.0008 1.52 (1.35–1.71) <0.0001 2.83 (2.27–3.52) <0.0001
Fourth suPAR quartile 1.28 (1.10–1.50) 0.0019 1.74 (1.55–1.96) <0.0001 5.49 (4.46–6.76) <0.0001
Multivariablea
Continuous suPAR 1.04 (0.95–1.14) 0.42 1.31 (1.22–1.39) <0.0001 1.76 (1.62–1.92) <0.0001
First suPAR quartileb 1 1 1
Second suPAR quartile 0.86 (0.72–1.02) 0.09 1.10 (0.96–1.25) 0.17 1.49 (1.13–1.97) 0.0050
Third suPAR quartile 1.11 (0.93–1.32) 0.24 1.44 (1.27–1.64) <0.0001 2.12 (1.63–2.75) <0.0001
Fourth suPAR quartile 1.00 (0.83–1.20) 0.97 1.61 (1.40–1.85) <0.0001 3.40 (2.64–4.39) <0.0001
Notes: aAdjusted for age, sex, Charlson score, blood eosinophil count, and C-reactive protein. bCut-offs for the suPAR quartiles: Q1: <2.9 ng/mL (n=980, 24.4%), Q2:
2.9–3.8 ng/mL (n=1003, 24.9%), Q3: 3.9–5.5 ng/mL (n=1014, 25.2%), Q4: ≥5.6 ng/mL (n=1025, 25.5%).
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; suPAR, soluble urokinase plasminogen activator receptor.
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yielded a sensitivity of 75.8% and specificity of 40.5% (PPV
30.9%, NPV 82.7%) for predicting 365-day mortality.
When 365-day event rates were stratified by both suPAR
quartiles and blood eosinophil groups (low/intermediate/
high), all-cause readmission events were evenly distributed
amongst both suPAR quartiles and blood eosinophil counts
(Figure 2A). In contrast, mortality events were increasing in
frequency with both increasing suPAR quartiles and decreas-
ing blood eosinophil counts, with the group of patients
belonging to the fourth suPAR quartile in combination with
low blood eosinophil counts showing the highest relative
mortality rate (53.0% group mortality) (Figure 2B).
Discussion
In this study, suPAR was associated with hospital read-
mission and all-cause mortality in acutely admitted COPD
patients. Median suPAR concentrations were consistently
higher at the time of admission in patients who were either
readmitted or died, and the risk of readmission and mor-
tality was particularly high for those with the highest
Table 5 HRs for Readmission and Mortality Within 365 Days Following Hospitalization in Patients with COPD (n=3849), for
Continuous Blood Eosinophil Count (Log2-Transformed) or Stratified by Low, Intermediate, and High Blood Eosinophil Count
Respiratory Readmission All-Cause Readmission All-Cause Mortality
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Unadjusted
Continuous 0.99 (0.96–1.03) 0.62 0.97 (0.94–0.99) 0.0071 0.83 (0.79–0.86) <0.0001
Lowb 1 1 1
Intermediate 0.85 (0.74–0.98) 0.026 0.92 (0.83–1.02) 0.12 0.55 (0.46–0.65) <0.0001
High 1.04 (0.89–1.21) 0.64 0.89 (0.79–1.00) 0.044 0.40 (0.32–0.50) <0.0001
Multivariablea
Continuous 1.01 (0.97–1.05) 0.56 0.97 (0.95–1.00) 0.051 0.85 (0.82–0.89) <0.0001
Lowb 1 1 1
Intermediate 0.88 (0.76–1.02) 0.10 0.92 (0.83–1.02) 0.12 0.60 (0.50–0.71) <0.0001
High 1.09 (0.93–1.27) 0.28 0.90 (0.80–1.02) 0.09 0.49 (0.39–0.62) <0.0001
Notes: aAdjusted for age, sex, Charlson score, suPAR, and C-reactive protein. bCut-offs defined as Low (<150 cells/μL, n=2366), Intermediate (150–300 cells/μL, n=886),
and High (>300 cells/μL, n=597).
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; suPAR, soluble urokinase plasminogen activator receptor.
Figure 2 Heatmap of 365-days all-cause readmission (A) and mortality (B) events in 3849 patients with chronic obstructive pulmonary disease acutely admitted to
a hospital, stratified by suPAR and blood eosinophil count on admission. Colors in the figure represent the percentage of patients with an event and the numbers represent
the total number of patients in strata. P-values represent Chi2-tests by suPAR quartile after stratification for blood eosinophil count, versus event-free patients.
Abbreviation: suPAR, soluble urokinase plasminogen activator receptor.
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suPAR level. Furthermore, high blood eosinophil counts
were associated with lower risk of all-cause mortality.
suPAR has previously been shown to be elevated in
a wide range of patients with chronic diseases such as
diabetes and cardiovascular disease.7 Beyond stable,
chronic diseases, we have previously shown elevated
suPAR to be a reliable marker for readmission and mor-
tality in unselected, acutely admitted medical patients in
an ED setting.7,20 In our previous study on a sub-set of the
present study population, we showed that suPAR was
strongly associated with 30- and 90-day mortality in
COPD patients.14 These findings are replicated in the
current, extended cohort and are also supported by our
findings of an association between suPAR and 365-day
mortality. When compared to healthy controls, several
studies have found elevated suPAR concentrations in
(AE)COPD patients.13,25,26 In contrast, a smaller study
failed to find elevated suPAR concentrations in patients
with stable COPD, perhaps due to the relatively mild
disease severity in patients enrolled, or due to differences
in the assays used to measure suPAR.27 A recent study has
shown that suPAR concentrations in COPD patients corre-
late with forced expiratory volume in 1 second (FEV1),
Tiffeneau Index as well as Medical Research Council
Dyspnea Score.28 Of note, suPAR was further elevated in
patients with more than two exacerbations per year.28
Several intrinsic risk factors for COPD readmission are
known, including low FEV1, hypoxia and comorbidities.
29
Indeed, comorbidity is likely an important factor in read-
mission risk as approximately 40% of the initial readmissions
in the present studywere due to respiratory disease, and more
than 30% of the cohort had a readmission caused be respira-
tory disease during the follow-up. This is a marked increase
from previous research estimating respiratory readmissions
to account for 27% of readmissions after AECOPD,30 per-
haps due to the present cohort including all-cause index
admissions. These findings combined with the high comor-
bidity burden in COPD patients highlight the need for
a relatively nonspecific disease marker, when searching for
a prognostic biomarker of readmission.31 However, suPAR
was not independently associated with respiratory readmis-
sions, and based on ROC curve analyses, the suPARAUC for
all-cause readmissions was poor. In contrast, suPAR demon-
strated an AUC of 0.71 (95% CI 0.69–0.72) for mortality in
our cohort and a negative predictive value of 84.2% for
a suPAR concentration above 4.45 ng/mL, suggesting that
measurement of suPAR on admission is an acceptable marker
for mortality risk assessment in clinical usage. A recent study
showed that suPAR outperformed standard emergency triage
in predictingmortality in ED patients, and the combination of
triage and suPAR >5.7 ng/L (equivalent to the fourth suPAR
quartile in the present study) yielded an AUC of 0.87
(0.82–0.93).32 This suggests that suPAR indeed is a viable
clinical marker for all-cause mortality in acutely admitted
patients with COPD.
Blood Eosinophil Count, Readmission and
Mortality in COPD
We observed a trend towards lower risk of all-cause read-
mission in patients with blood eosinophil counts above
300 cells/μL. With respiratory readmissions in the present
study being dominated by exacerbations, our results stand
in contrast to the Copenhagen General Population Cohort,
as well as the COPDGene and ECLIPSE cohorts, where
increasing blood eosinophil count was reported to associ-
ate with increased risk of recurrent exacerbations in stable
COPD.18,23 However, there is conflicting evidence with
analyses of the BODE, CHAIN and SPIROMICS cohorts
showing no association between blood eosinophils and
increased exacerbation risk.33,34 Furthermore, and perhaps
more relevant to the setting of the present study, a recent
study on AECOPD also showed an increased risk of (re)
exacerbation in patients with elevated blood eosinophils.35
Despite the conflicting findings on readmission, our
findings on lower risk of mortality in patients with blood
eosinophil counts above 300 cells/μL are seemingly well
supported in the literature with regard to AECOPD.33,35
While the overall role and mechanisms of eosinophils in
COPD are still debated, post hoc analyses of the WISDOM
and FLAME trials, as well as a study by Pascoe and collea-
gues, have found that patients with elevated blood eosino-
phil count respond well to corticosteroids during
AECOPD.22,36,37 This might in part explain the relative
increase in mortality in patients with lower blood eosinophil
counts who could be considered to have a more neutrophilic
inflammatory profile, representing a COPD phenotype with
poorer bronchodilator and steroid therapy response, and
thus a relatively high short-term mortality due to low treat-
ment efficacy. Indeed, two smaller studies have previously
associated low eosinophil counts to increased mortality in
AECOPD.38,39 Eosinopenia (defined as <40 cells/μL) was
associated with readmission within 30 days and has been
proposed as a part of an AECOPD mortality prediction
score.38,40 A plethora of biomarkers for readmission and
mortality in (AE)COPD have been suggested.41,42 Common
Håkansson et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
International Journal of Chronic Obstructive Pulmonary Disease 2020:15740
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
23
0.
20
0 
on
 0
7-
Ju
l-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
themes include either a panel of biomarkers or demographi-
cal data to calculate risk, but there is little coherence
between studies regarding which parameters to include.
In terms of clinical performance, a cut-off of 150 cells/µL
reached a similar negative predictive value (82.7%) for
365-day mortality prediction as suPAR. Interestingly, our
study found that high suPAR concentrations (>3.5 ng/mL)
were associated to higher mortality, with a majority (53.0%)
of mortality events occurring in patients with low blood
eosinophil counts and high suPAR concentrations. This sug-
gests that concurrent measurement of blood eosinophils and
suPAR could hold clinical value in improving risk assess-
ment in COPD patients in comparison to suPAR or blood
eosinophils alone.
Limitations
A limitation of the present study is the lack of information on
patient smoking status, as smoking has been shown to affect
suPAR concentrations and isoform expression.43,44 suPAR
concentrations decrease with smoking cessation, but those
with the highest suPAR concentrations while smoking also
have the highest suPAR concentrations after cessation,45 and
as such, we believe this possible bias to be non-differential.
Furthermore, the present trial is a single-center trial, which
could mean that the results are less representative for other
hospitals. Confounding due to the lack of information on
other clinical risk factors for readmission and mortality,
such as FEV1 and dyspnea grade cannot be dismissed. The
Danish patient registries used are validated, but some mis-
diagnoses are inevitable. All analyses were based on a single
measurement at the time of index admission and thus any
changes due to treatment or simple disease progression dur-
ing in-hospital stay were not assessed.
In contrast to other cohorts of COPD patients, most of the
patients (55%) were women which could suggest a selection
bias in our cohort. However, this could also be due to the
relatively high prevalence of smoking women in Denmark,46
giving rise to a significant number of Danish women with
COPD,47 along with a general tendency for men with COPD
in being less inclined to contact healthcaremodalities overall.48
Moreover, there is evidence suggesting that women are prone
to frequent, as well as more severe, exacerbations.49,50
Conclusion
To conclude, elevated suPAR was associated with increased
readmission and mortality risk in COPD patients, while
high blood eosinophil count was associated with lower
mortality risk in COPD patients, suggesting that both
biomarkers are useful in COPD. Interestingly, elevated
suPAR is associated with higher mortality even in patients
with low and normal blood eosinophil counts.
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